{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T12:22:55Z","timestamp":1773145375693,"version":"3.50.1"},"reference-count":30,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2011,4,20]],"date-time":"2011-04-20T00:00:00Z","timestamp":1303257600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2011,6]]},"abstract":"<jats:p>The prevalence of obesity, a major risk factor for many chronic diseases, has risen in most developed countries over the past several decades. The economic burden for both public and private health care systems is substantial. Although certain non\u2010pharmaceutical interventions have been proven efficacious in specific populations, the lack of scalability has caused many of these programmes to fail in sustainably decreasing the percent of patients who are overweight or obese. The benefits of other interventions, such as pharmaceutical agents, medical devices and surgery, should therefore be carefully considered: this article focuses on the first of these strategies. Various pharmaceutical products have been plagued with safety concerns or patient non\u2010adherence because of unpleasant side effects. Therefore, the need for additional antiobesity drugs that are both safe and effective is considerable. This article discusses the regulatory landscape for the development of new antiobesity compounds in the United States and Europe and considers the ramifications of greater or lesser regulatory burdens.<\/jats:p>","DOI":"10.1111\/j.1463-1326.2010.01353.x","type":"journal-article","created":{"date-parts":[[2010,12,8]],"date-time":"2010-12-08T10:41:21Z","timestamp":1291804881000},"page":"490-497","source":"Crossref","is-referenced-by-count":25,"title":["Pharmaceutical interventions for obesity: a public health perspective"],"prefix":"10.1111","volume":"13","author":[{"given":"E.","family":"Caveney","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. J.","family":"Caveney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Somaratne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. R.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Gourgiotis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,4,20]]},"reference":[{"key":"e_1_2_9_2_2","unstructured":"World Health Organization.Available from URL:http:\/\/www.who.int\/topics\/obesity\/en. Accessed 18 July2010."},{"key":"e_1_2_9_3_2","unstructured":"World Health Organization\/International Obesity Task Force.The Asia\u2010Pacific Perspective: Redefining Obesity and its Treatment.Australia: Health Communications Australia Pty Limited 2000."},{"key":"e_1_2_9_4_2","unstructured":"World Health Organization.Obesity and Overweight. Fact Sheet Number 311.2006."},{"key":"e_1_2_9_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.2014"},{"key":"e_1_2_9_6_2","unstructured":"World Health Organization Europe.10 things you need to know about obesity. November2006."},{"key":"e_1_2_9_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60269-X"},{"key":"e_1_2_9_8_2","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.28.5.w822"},{"key":"e_1_2_9_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-008-9239-1"},{"key":"e_1_2_9_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.167.8.766"},{"key":"e_1_2_9_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-789X.2008.00521.x"},{"key":"e_1_2_9_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-789X.2008.00472.x"},{"key":"e_1_2_9_13_2","unstructured":"The Seventh Report of the Joint National Committee on Prevention Detection Evaluation and Treatment of High Blood Pressure.Available from URL:http:\/\/www.nhlbi.nih.gov\/guidelines\/hypertension\/jnc7full.pdf. Accessed 18 July2010."},{"key":"e_1_2_9_14_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-S011"},{"key":"e_1_2_9_15_2","unstructured":"International Diabetes Federation: Chapter 5 Lifestyle Management. Available from URL:http:\/\/www.idf.org\/webdata\/docs\/GGT2D%2005%20Lifestyle%20management.pdf. Accessed 26 July2010."},{"key":"e_1_2_9_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2004.02.001"},{"key":"e_1_2_9_17_2","unstructured":"The U.S. Preventive Services Task Force Screening for Obesity in Adults Recommendations and Rationale.Available from URL:http:\/\/www.uspreventiveservicestaskforce.org\/3rduspstf\/obesity\/obesrr.htm. Accessed 5 November2010."},{"key":"e_1_2_9_18_2","unstructured":"FDA.Guidance for Industry: Developing Products for Weight Management. Available from URL:http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm071612.pdf. Accessed 18 July2010."},{"key":"e_1_2_9_19_2","unstructured":"EMA.Guideline on Clinical Evaluation of Medicinal Products Used in Weight Control. Available from URL:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003264.pdf. Accessed 18 July2010."},{"key":"e_1_2_9_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-010-0092-9"},{"key":"e_1_2_9_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-008-0029-7"},{"key":"e_1_2_9_22_2","first-page":"34","article-title":"Regulatory landscapes for future antidiabetic drug development (Part I): FDA guidance on assessment of cardiovascular risks.","author":"Caveney E","year":"2010","journal-title":"J Clin Stud"},{"key":"e_1_2_9_23_2","first-page":"38","article-title":"Regulatory landscapes for future antidiabetic drug development (Part II): EMA guidance on assessment of cardiovascular risks.","author":"Turner JR","year":"2010","journal-title":"J Clin Stud"},{"key":"e_1_2_9_24_2","unstructured":"McCaughanM HelblingL.The RPM Report2010;4:1\u201311."},{"key":"e_1_2_9_25_2","volume-title":"Introduction to Statistics in Pharmaceutical Clinical Trials.","author":"Durham TA","year":"2008"},{"key":"e_1_2_9_26_2","unstructured":"Food and Drug Administration 2008. The Sentinel Initiative: National Strategy for Monitoring Medical Product Safety. Available from URL:http:\/\/www.fda.gov\/downloads\/Safety\/FDAsSentinelInitiative\/UCM124701.pdf. Accessed 24 October 2010."},{"key":"e_1_2_9_27_2","unstructured":"110th US Congress. Food and Drug Administration Amendments Act; September2007. Available from URL:http:\/\/www.fda.gov\/RegulatoryInformation\/Legislation\/FederalFoodDrugandCosmeticActFDCAct\/SignificantAmendmentstotheFDCAct\/FoodandDrugAdministrationAmendmentsActof2007\/FullTextofFDAAALaw\/default.htm. Accessed 18 July 2010."},{"key":"e_1_2_9_28_2","unstructured":"FaichG.Evaluation of REMS. Presentation given at the FDAnews\/United BioSource Corporation\/Center for Medicine in the Public Interest \u2018Drug Management and Drug Safety Summit'.Washington DC:National Press Club 29 October2008."},{"key":"e_1_2_9_29_2","unstructured":"TurnerJR.Drug safety medication safety patient safety: an overview of recent FDA Guidances and initiatives.Regulatory Rapporteur2009;6:4\u20138."},{"key":"e_1_2_9_30_2","unstructured":"SutterS DavisJ.FDA EMA decisions on Avandia reflect the power of REMS. \u201cThe Pink Sheet:\u201d Prescription Pharmaceuticals and Biotechnology. 27 September2010; 1 and4\u20136."},{"key":"e_1_2_9_31_2","unstructured":"TurnerJR.Integrated drug safety: benefit\u2010risk assessments in drug development and use.Appl Clin Trials in press."}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1463-1326.2010.01353.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/j.1463-1326.2010.01353.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T04:45:19Z","timestamp":1761885919000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/j.1463-1326.2010.01353.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,20]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["10.1111\/j.1463-1326.2010.01353.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1463-1326.2010.01353.x","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,20]]}}}